MedTrace Logo

Bioequivalence Study of Lithium Carbonate 300 mg Tablets. Actilitio® in Healthy Subjects

NCT06861842 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-06

No results posted yet for this study

Summary

A bioequivalence study of lithium carbonate will be developed in 24 healthy subjects, in fasting condition

Conditions

  • Healthy
  • Healthy Donors

Interventions

DRUG

Theralite®

Reference

DRUG

Actilitio®

Test

Sponsors & Collaborators

  • Centro de Atencion e Investigacion Medica

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • Colombia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06861842 on ClinicalTrials.gov